Bortezomib Against Refractory Antibody-Mediated Rejection After ABO-Incompatible Living-Donor Liver Transplantation: Dramatic Effect in Acute-Phase?

Antibody-mediated rejection (AMR) is a refractory rejection after donor-specific antibody-positive or ABO blood-type incompatible (ABOi) organ transplantation. Rituximab dramatically improved the outcome of ABOi living-donor liver transplantation (LDLT); however, an effective treatment for posttrans...

Descripción completa

Detalles Bibliográficos
Autores principales: Tajima, Tetsuya, Hata, Koichiro, Okajima, Hideaki, Nishikori, Momoko, Yasuchika, Kentaro, Kusakabe, Jiro, Yoshizawa, Atsushi, Fukumitsu, Ken, Anazawa, Takayuki, Tanaka, Hirokazu, Wada, Seidai, Doi, Junshi, Takaori-Kondo, Akifumi, Uemoto, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Liver Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791599/
https://www.ncbi.nlm.nih.gov/pubmed/31723586
http://dx.doi.org/10.1097/TXD.0000000000000932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791599/
https://www.ncbi.nlm.nih.gov/pubmed/31723586
http://dx.doi.org/10.1097/TXD.0000000000000932

Ejemplares similares